Generic Zykadia Availability
Last updated on Apr 10, 2025.
Zykadia is a brand name of ceritinib, approved by the FDA in the following formulation(s):
ZYKADIA (ceritinib - capsule;oral)
-
Manufacturer: NOVARTIS
Approval date: April 29, 2014
Strength(s): 150MG (discontinued) [RLD]
ZYKADIA (ceritinib - tablet;oral)
-
Manufacturer: NOVARTIS
Approval date: March 18, 2019
Strength(s): 150MG [RLD]
Is there a generic version of Zykadia available?
No. There is currently no therapeutically equivalent version of Zykadia available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zykadia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Patent 7,893,074
Issued: February 22, 2011
Inventor(s): Garcia-Echeverria; Carlos et al.
Assignee(s): Novartis AG (Basel, CH); IRM LLC (Hamilton, BM)Novel pyrimidine derivatives of formula I ##STR00001## to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Patent expiration dates:
- April 25, 2026✓✓
- April 25, 2026
-
2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Patent 7,964,592
Issued: June 21, 2011
Inventor(s): Garcia-Echeverria; Carlos et al.
Assignee(s): Novartis AG (Basel, CH)Novel pyrimidine derivatives of formula I ##STR00001## to process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Patent expiration dates:
- April 29, 2028✓✓
- April 29, 2028
-
Compounds and compositions as protein kinase inhibitors
Patent 8,039,479
Issued: October 18, 2011
Inventor(s): Michellys; Pierre-Yves et al.
Assignee(s): IRM LLC (Hamilton, BM)The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
Patent expiration dates:
- June 29, 2030✓✓
- June 29, 2030
-
Compounds and compositions as protein kinase inhibitors
Patent 8,377,921
Issued: February 19, 2013
Inventor(s): Michellys Pierre-Yves & Pei Wei & Marsilje Thomas H. & Chen Bei & Uno Tetsuo
Assignee(s): IRM LLCThe invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
Patent expiration dates:
- November 20, 2027✓
- November 20, 2027
-
Compounds and compositions as protein kinase inhibitors
Patent 8,399,450
Issued: March 19, 2013
Inventor(s): Michellys Pierre-Yves & Pei Wei & Marsilje Thomas H. & Lu Wenshuo & Chen Bei & Uno Tetsuo & Jin Yunho & Jiang Tao
Assignee(s): IRM LLCThe invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
Patent expiration dates:
- November 20, 2027✓✓
- November 20, 2027
-
Methods of using ALK inhibitors
Patent 8,703,787
Issued: April 22, 2014
Inventor(s): Li Nanxin & Harris Jennifer Leslie & McNamara Peter & Sun Fangxian
Assignee(s): IRM LLCThe invention provides methods for using compounds of Formula (I) for treating an EML4-ALK mediated condition such as EML4-ALK non-small cell lung cancer, and optionally resistant to crizotinib; wherein R, R, R, R, Rand Rare as defined above.
Patent expiration dates:
- February 2, 2032✓
- February 2, 2032
-
Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Patent 9,309,229
Issued: April 12, 2016
Inventor(s): Feng Lili & Gong Baoqing & Karpinski Piotr H. & Waykole Liladhar Murlidhar
Assignee(s): Novartis AGThe present invention describes specific crystalline forms of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropylsulfonyl)phenyl)-2,4-diamine. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.
Patent expiration dates:
- January 18, 2032✓✓
- January 18, 2032
More about Zykadia (ceritinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
